Beacon Biosignals announced an oversubscribed $86 million Series B funding round to build the world's largest neurodiagnostic dataset and advance the clinical application of AI-driven biomarkers for brain health. The round was backed by premier healthcare and technology investors, including Innoviva, Google Ventures (GV), Nexus NeuroTech Ventures, S32, Catalio Capital Management, and Takeda, bringing the company's total funding to more than $121 million.
Revolutionary Home-Based Brain Monitoring Technology
Unlike consumer wearables that infer brain activity indirectly, Beacon's FDA-cleared Waveband device directly measures the brain's electrical activity (EEG) during sleep and wake, bringing gold-standard neurophysiology out of the lab and into patients' homes. The resulting biosignal data provide ecologically valid, longitudinal measures of brain function across diverse populations, fueling Beacon's foundation model of brain activity trained on millions of hours of EEG data to uncover early disease signatures and predict treatment response.
"Our mission is to make brain function measurable and actionable at scale," said Jacob Donoghue, MD, PhD, CEO and co-founder of Beacon Biosignals. "By training AI on millions of hours of real-world brain data, we're beginning to map the signals of health and disease in ways that can accelerate drug development and ultimately improve how patients are diagnosed and treated."
Comprehensive Sleep and Brain Health Platform
The company's core technology, the Beacon Platform, unites large-scale, clinically validated EEG data with advanced AI to generate objective, quantitative biomarkers of brain function through sleep. Sleep provides a critical yet underutilized window into brain health, serving as both a key symptom and a mechanistic pathway across conditions such as clinical depression, Parkinson's disease, Alzheimer's disease, and sleep apnea.
The Series B follows Beacon's recent acquisition and integration of CleveMed's home sleep-testing (HST) technology, expanding the Beacon Platform beyond EEG to include airflow, respiratory effort, and oxygen saturation. Together, these capabilities form the industry's most comprehensive, clinically integrated ecosystem for measuring and understanding sleep and brain health.
Extensive Pharmaceutical Industry Partnerships
Beacon's technology now supports research and development programs with more than half of the world's top ten biopharmaceutical companies, as well as a growing portfolio of leading biotechs. These collaborations leverage AI-derived biomarkers to accelerate CNS drug development and commercialization, providing quantitative clinical endpoints, enabling more precise patient selection, and helping close care gaps in neurological and psychiatric disease. Current named partners include companies such as Takeda, UCB, Mineralys, Syndeio, and other leaders in the field.
Through the Beacon Platform's AI-driven EEG analytics, the company helps partners identify dose-dependent drug effects, characterize patient populations, expand labeling opportunities, and detect disease progression early.
Industry Expert Perspectives
"For too long, neurology and psychiatry have lacked the kind of objective biomarkers that revolutionized other areas of medicine," said Anthony Philippakis, MD, PhD, General Partner at GV. "Beacon's ability to translate real-world sleep EEG into actionable insights brings that same precision to brain health, enabling more targeted, data-driven treatment development."
Pavel Raifeld, CEO of Innoviva, added: "We're thrilled to partner with Beacon as they build the infrastructure for precision neuroscience. By connecting real-world brain data to both drug development and clinical care, Beacon is building a category-defining business positioned for sustained growth and broad impact in CNS therapeutics."
Clinical Advantages Over Consumer Devices
Consumer devices typically infer sleep from heart rate or movement, while clinical sleep monitoring directly measures brain function. Beacon Biosignals delivers gold-standard EEG and cardiopulmonary data at home, enabling both clinical diagnostics and research at scale. The company's FDA-cleared wearable medical devices, the Beacon Waveband and SleepView, provide the same clinical-grade insights as an overnight lab study but with far lower cost and patient burden.
With this new investment, Beacon is scaling its technology and operations to accelerate neurobiomarker discovery and broaden clinical adoption, positioning the company to advance precision medicine approaches across neurology, psychiatry, and sleep medicine.
